# A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

> **NCT06095505** · PHASE2 · RECRUITING · sponsor: **Puma Biotechnology, Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Alisertib

## Key facts

- **NCT ID:** NCT06095505
- **Lead sponsor:** Puma Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-08
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-10-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06095505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06095505, "A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06095505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*